Pharmacology - Anticoagulation Flashcards
What types of antiplatelet agents are there and indications
1) inhibitors of prostaglandin synthesis: aspirin
2) inhibitors of ADP-induced platelet aggregation: clopidogrel, ticagrelor
3) blockers of platelet glycoprotein IIb/IIIa receptors: abciximab
4) phosphodiesterase inhibitors: dypyridamole
-indications for antiplatelets: IHD, TIA, CVA, post ACS intervention
What is the mechanism of action of aspirin
irreversibly inhibits COX 1/2 enzyme
causes reduced TXA2
which reduces platelet aggregation
What is the mechanism of action of clopidogrel
-inhibition of ADP-induced platelet aggregation by blocking the ADP receptor
-pharmacokinetics: prodrug, metabolised by liver to active metabolite, t1/2 0.5-1 hour
80% platelet activity inhibited in 5 hours of oral dose
50% excreted in urine, 50% excreted in faeces
- dose: loading of 300-600mg or 75mg daily
- duration of effect: 7-10 days
- adverse effects: bleeding, rash, diarrhoea, abdominal pain, reflux, gastric ulcers
How does heparin work, how is it administered and what are some side effects
-mechanism:
binds to antithrombin III and enhances its activity
speeds up interaction between antithrombin III and factors 2, 9, 10 via conformational change
promotes inhibition of these factors by complexing with them
- administration: IV or SC, therapeutic vs prophylactic dose
- adverse effects: bleeding, allergy, allopecia, HIT
-reversal: protamine is highly charged and combines with negatively charged Heparin, causing inactivation
1mg protamine neutralises 100 units heparin and 1mg enoxaparin
Compare LMWH and UFH
-Low molecular weight (enoxaparin) -
short chains, only inhibits factor 10a, higher bioavailability, SC form
reduced bleeding risk, less HIT, less frequent dosing, less monitoring, needs renal adjustment
-High molecular weight (heparin) -
unfractioned, inhibits all 3 factors, given IV, short half life
higher risk of HIT, more monitoring required, needs continuous infusion
What are the types of thrombolytic agents
- mechanism: rapidly lyse thrombi by catalyzing the formation of plasmin from plasminogen
1) streptokinase: synthesised from streptococci, needs loading and infusion, lower risk of haemorrhagic stroke
2) tPA: endogenous, activates plasminogen bound to fibrin (confines fibrinolysis), can be used as a push dose - uses: AMI, unstable PE, acute ischaemic stroke
- adverse effects: haemorrhagic stroke (most common), GI bleed, allergy
What is the mechanism of action of rivaroxaban
-mechanism: direct inhibitor of factor Xa
-pharmacokinetics: high oral bioavailability, small VOD, peak concentration in 2-4 hours, highly protein bound
2/3 metabolised by the liver, 1/3 excreted unchanged by kidney
substrate for P450 system, so drugs that inhibit CYP3A4 cause increased rivaroxaban effect
- advantages over warfarin: more rapid onset, wider therapeutic index, INR monitoring not required
- disadvantages compared to warfarin: need dose adjustment in renal failure, not suitable for dialysis patients
- can measure anti-factor Xa activity in bloods
- there is no specific antidote or reversal agent
What is the mechanism of action and pharmacokinetics of warfarin and what products are used to reverse it
-mechanism: inhibits vitamin K epoxidereductase (normally converts vitamin K to its active form)
prevents the activation of vitamin K dependent clotting factors (2, 7, 9, 10, protein c/s)
- pharmacokinetics: 100% oral bioavailability, 99% protein bound, t1/2 36 hours, 8-12 hour delay in action
- reason for delay of onset: presence of active vitamin K before dose
- toxicity: crosses placenta, cutaneous necrosis, bleeding
-interactions: involved enzyme induction/inhibition of CYP2C9
medications that decrease INR (inducers) = rifampicin, barbiturates, phenytoin, carbamazapine
medications that increase INR (inhibitors) = amiodarone, metronidazole, fluconazole, aspirin, heparin
-reversal: vitamin K, FFP, prothrombin complex (contains factors 2, 9, 10)
How long does it take vitamin K to work in reversing warfarin
24 hours
Describe mechanisms by which drugs interact with warfarin
pharmacokinetic:
enzyme inhibitors causing increased INR, enzyme inducers causing decreased INR
pharmacodynamic:
synergism (aspirin affects platelet function), competitive antagonism (presence of vitamin K)